Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Protalix BioTherapeutics (PLX) Interest & Investment Income (2024 - 2025)

Protalix BioTherapeutics has reported Interest & Investment Income over the past 2 years, most recently at $266000.0 for Q4 2025.

  • Quarterly results put Interest & Investment Income at $266000.0 for Q4 2025, down 19.15% from a year ago — trailing twelve months through Dec 2025 was $1.2 million (changed N/A YoY), and the annual figure for FY2025 was $1.1 million, down 16.63%.
  • Interest & Investment Income for Q4 2025 was $266000.0 at Protalix BioTherapeutics, down from $289000.0 in the prior quarter.
  • Over the last five years, Interest & Investment Income for PLX hit a ceiling of $374000.0 in Q2 2024 and a floor of $212000.0 in Q3 2024.